Emerging in the field of obesity therapy, retatrutide is a different method. Unlike many current medications, retatrutide functions as a twin agonist, concurrently targeting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. The concurrent engagement promotes multiple advantageous effects, like enhanced